Aim:This study aimed to understand the current level of linezolid (LNZ) resistance in Streptococcus pneumoniaeisolates reported over the past 10 years. Material & methods:An electronic search was conducted for the following keywords: ((Streptococcus pneumoniae[title/abstract]) OR (Pneumococcus[title/abstract]) OR (Pneumococci [title/abstract]) AND (linezolid [title/abstract]) OR (Zyvox [title/abstract])) OR (Zyvoxid [title/abstract])). Result:Out of all the studies, 80 had a cross-sectional design, while 11 followed a cohort approach. The prevalence of LNZ resistance among S. pneumoniaeisolates ranged from 0% to 4.86%. Discussion:Urgent, high-powered, randomized, controlled trials with participants from endemic regions are needed to gain a comprehensive understanding of the impact on and significance of LNZ treatment to patients.